Articles tagged with Drug Discovery
Researchers isolated three potent anti-HIV compounds from Daphne pseudomezereum, with EC₅₀ values around 1 nM and IC50 > 5 μM. The findings suggest a promising approach to developing novel drugs with superior anti-HIV activity.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
Researchers from IOCB Prague have developed a compound that could treat alopecia areata by targeting the immune system. The substance, a series of prodrugs based on derivatives of itaconic acid, has shown efficacy in mice tests and may be administered orally.
Insilico Medicine has secured a $110 million Series E financing to accelerate the advancement of its AI-driven drug discovery pipeline and platform developments. The funds will focus on refining AI models and algorithms, as well as advancing clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment.
A new study reports that Raman spectroscopy, a noninvasive technique, can distinguish between abnormal FCD type II tissue and healthy brain cells with remarkable accuracy. This method could provide real-time guidance for surgeons to more accurately identify and remove affected tissue during surgery.
Dr. Ronald Newbold has been appointed as the permanent CEO of Empire Discovery Institute (EDI), a non-profit drug discovery and development accelerator. With over 30 years of business development experience, Dr. Newbold will lead EDI's growth and expansion, including the addition of new programs and partnerships.
Scientists at Sanford Burnham Prebys discovered novel fragments of future drugs that selectively inhibit the enzyme VHR, which plays a role in controlling the immune system's response to danger. The findings may lead to the development of new therapies for sepsis and septic shock.
Rentosertib, a breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF), has been granted an official generic name by the USAN Council. The drug's development was accelerated using generative AI, identifying TNIK as a promising target and designing small-molecule compounds in just 18 months.
Insilico Medicine has deployed the first bipedal humanoid AI scientist, Supervisor, to aid in data acquisition and generation for training embodied AI systems. The humanoid will assist with lab tours, telepresence, tracking, and supervision, bridging the gap between human-free fully-autonomous robotics facilities.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
A new study discovered rare gene variants in Asian Indian people that increase the risk of Type 2 diabetes, providing a window into targeted treatment. The findings suggest that these variants can be used to create personalized medications that target specific proteins or pathways.
Researchers from NUS have pioneered a new catalytic transformation that converts epoxides into fluorinated oxetanes, a coveted class of drug molecules. The discovery potentially opens the door to new medicines and offers a reliable route to incorporate these motifs into the design of novel small-molecule therapeutics.
The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.
Researchers at Salk Institute discover SSRIs like Prozac regulate immune response, preventing sepsis in mice. The findings suggest a potential new use for the popular drug, which could lead to life-saving treatments and enhanced global preparedness for pandemics.
Donald Patrick McDonnell, a professor at Duke University School of Medicine, has been awarded the Endocrine Society's John D. Baxter Prize for his research on hormone therapies for treating breast and prostate cancers. His work led to the discovery of novel treatments for these cancers and has improved patient care.
PairMap overcomes limitations of traditional methods by introducing intermediate compounds to predict binding affinities with high accuracy. The approach minimizes calculation errors, improves convergence, and reduces computational costs for complex transformations.
ApoB100 protein structure revealed for the first time, allowing for more precise testing and treatment of high cholesterol and heart disease. The discovery may lead to new drugs targeting LDL particles, reducing side effects of statin drugs.
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
A new method of testing the metabolic effects of thousands of active substances at the same time has been developed by researchers at the University of Basel, providing valuable insights into the modes of action of known medications. The study reveals previously unknown mechanisms and potential side effects.
Researchers at SickKids have identified the KCNB2 gene as a key target for treating medulloblastoma. Targeting this gene can enhance current cancer treatments and tackle tumour growth without impacting surrounding healthy cells.
Critical Path Institute's Translational Therapeutics Accelerator (TRxA) is launching its 2025 global Request for Proposals to support academic researchers in bridging the 'valley of death' in drug development. The program aims to enable the transition of innovative therapeutics from lab to patients.
The article reviews metabolomics-driven approaches for identifying therapeutic targets in drug discovery, highlighting the challenges and limitations of current methods. Emerging technologies like single-cell metabolomics, artificial intelligence, and mass spectrometry imaging are explored to enhance target discovery.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Positive Phase 1 trial results suggest ISM5411's gut-restrictive property and favorable pharmacokinetic profile, validating its potential for treating inflammatory bowel disease. Insilico Medicine expects to initiate a Phase 2 proof-of-concept study in active ulcerative colitis patients.
A University of Oklahoma research team has developed a breakthrough method of adding a single nitrogen atom to bioactive molecules, transforming them into new pharmacophores. This process, called skeletal editing, could open up uncharted regions of chemical space in drug discovery, making existing drugs cheaper and more accessible.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.
A team of researchers at USC will receive funding to test a novel approach to slowing age-related cognitive decline, targeting the brain's lymphatic system. The grant aims to delay the onset of Alzheimer's and Parkinson's disease by clearing waste buildup.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
SPACe enables researchers to analyze large datasets in an efficient way, capturing the full diversity of cellular responses. The platform provides a more nuanced understanding of how drugs interact with cells, revealing insights into mechanisms beyond cell death.
Insilico Medicine has nominated ISM8969, an orally available NLRP3 inhibitor, as a potential treatment for various inflammatory diseases. The compound has shown promising results in preclinical evaluation studies, including balanced druggability and efficacy against inflammation.
Insilico Medicine has successfully integrated cutting-edge generative AI models into its platform, achieving significant increases in accuracy and speed. The company's AI-powered solutions have shown promising results in preclinical candidates and Phase II clinical trials.
Insilico Medicine has developed an innovative platform using generative AI to discover novel molecules. The company has nominated over 20 preclinical candidates and received IND clearance for 10 molecules.
The new effort aims to rapidly transform academic breakthroughs into life-saving therapies for a range of medical conditions. Autobahn Labs will invest up to $5 million per selected project to support the development of new pharmaceuticals.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
Researchers found neurotransmitters GABA and choline in the venom of estuarine and reef stonefish, which can modulate cardiovascular function. The discovery could aid in targeted treatments and venom-derived compound development for drug discovery.
Researchers at New York University developed a mathematical approach, Crystal Math, to predict molecular crystal structures in hours, bypassing weeks or months of supercomputer processing. This breakthrough could speed up R&D for drugs and electronic devices.
Argonne is using AI, high performance computing, simulation and structural biology to research novel ways to fight cancer and transform vaccine discovery. The lab aims to compress the drug discovery timeline and develop toolkits for broadly effective vaccines against multiple viral threats.
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.
Insilico Medicine has entered into a revolving loan facility of up to US$100 million with HSBC, enabling the company's global expansion and AI-driven innovation in biotechnology. The credit line will support Insilico's proprietary novel drug discovery pipeline and its end-to-end diversified AI platform, Pharma.AI.
The new portal connects genetic variant data with protein sequence and structural information, enabling easy visualization of variants on protein 3D structures. This facilitates the analysis of genetic variants' impact on protein function and structure.
Dr. Wai Hong Lo, PhD, has been appointed as the new Editor-in-Chief of ASSAY and Drug Development Technologies, succeeding Dr. Bruce Melancon. Dr. Lo aims to enhance online accessibility, incorporate visuals, and increase social media engagement to reach a broader audience.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.
Researchers are creating microphysiological systems to simulate infection and treatment in vitro, linking human lung and brain tissue models. This project aims to explore the relationship between respiratory diseases and neurological symptoms, potentially leading to new treatments.
Researchers found that the oral medication palbociclib stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis, a form of appendix cancer often resistant to standard chemotherapy. The study's findings introduce a first targeted therapy for this rare disease.
Researchers at KAIST successfully developed single-atom editing technology that maximizes drug efficacy by converting oxygen atoms into nitrogen atoms in furan compounds. This breakthrough technology enables selective editing of complex natural products or pharmaceuticals, opening new doors for building libraries of drug candidates.
Researchers have developed a cell culture platform to form two distinct, interconnected vascular networks, replicating human physiology and reducing animal testing costs. This breakthrough enables the study of cellular interactions in vascularized tissues.
Researchers at IOCB Prague successfully isolated the proteasome enzyme complex of the T. vaginalis parasite, enabling them to develop new medicines that can target this parasite without harming humans. This breakthrough has critical implications for treating trichomoniasis and reducing HIV risk.
Scientists at The Wistar Institute have identified a novel series of SARS-CoV-2 Mpro inhibitors that effectively inhibit viral replication in vitro against multiple COVID variants. These compounds also synergize with existing antivirals, offering promise for developing future therapies.
Recent research highlights microwave-induced synthesis as a transformative potential in drug discovery and development. This efficient technique enables rapid preparation of diverse N-heterocycles, including biologically active molecules such as pyrimidines, thiazoles, and quinolines.
Removing protected class regulation from Medicare Part D policies could reduce US prescription drug spending, potentially saving $47 billion between 2011-2019. The study found that rebates for protected classes of drugs grew at a slower pace than non-protected classes.
Researchers created SmartCADD, an AI-powered virtual tool combining quantum mechanics and Computer Assisted Drug Design techniques. The tool speeds up the screening of chemical compounds, significantly reducing drug discovery timelines and identifying promising HIV drug candidates.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
KiNet is an interactive web portal that enables researchers to visualize and study kinase-substrate interactions in systemwide contexts. This facilitates the understanding of kinase functions and their implications in diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.
Researchers at the University of Copenhagen's Quantum for Life Centre have developed a new mathematical recipe to make quantum simulators more scalable and efficient. This breakthrough could speed up the development of new medicines from years to months by predicting how molecules behave in the human body before laboratory trials.
Researchers at UConn have discovered a novel miRNA-141-3p inhibitor that successfully reduces stroke damage and extinguishes inflammatory fires in the brain. The treatment has shown swift restoration of motor function and memory in mouse models, offering new hope for patients affected by strokes.
Researchers at the University of Virginia Health System have identified a crucial biological switch that regulates renin production in certain cells, allowing them to control blood pressure. This discovery provides important direction for future research into high blood pressure and cardiovascular disease treatment.